Global R&D Pipeline
My Favorite
Hot Targets:
CD19
Back
Total number of drugs
934
Phase II and later clinical stages
6.4%
Involving companies
635
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SA-203 | SA-203 | Universal CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases | BCMA inhibitors CD19 inhibitors | Wuhan Si'an Medical Technology Co., Ltd. | Wuhan Si'an Medical Technology Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | SA-203 | - | - | detail > | |
| GD-CO19 | GD-CO19 | T-lymphocyte cell therapy | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD19 inhibitors | ManysmarT Therapeutics Inc. | ManysmarT Therapeutics Inc. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | GD-CO19 | - | - | detail > | |
| Chimeric antigen receptor T cells targeling CD19& CD22 (Pregene) | Chimeric antigen receptor T cells targeling CD19& CD22 (Pregene) | CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD19 inhibitors CD22 inhibitors | Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. | Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. | Preclinical | Preclinical | - | - | - | Orphan Drug（United States） | - | - | - | - | Chimeric antigen receptor T cells targeling CD19& CD22 (Pregene) | - | - | detail > | |
| IM-1920 | IM-1920 | Bispecific antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD19 inhibitors CD20 inhibitors | ITabMed Co., Ltd. | ITabMed Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | IM-1920 | - | - | detail > | |
| CD19 and CD38 dual-target CAR-T cells | CD19 and CD38 dual-target CAR-T cells | CAR-T | Neoplasms Hemic and Lymphatic Diseases | CD19 inhibitors CD38 inhibitors | Beijing University of Traditional Chinese MedicineGuangdong Junhou Biomedical Co., Ltd. | Beijing University of Traditional Chinese MedicineGuangdong Junhou Biomedical Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | CD19 and CD38 dual-target CAR-T cells | - | - | detail > | |
| CD19/CD247 CAR-T (Nanjing Legend Biotech ) | CD19/CD247 CAR-T (Nanjing Legend Biotech ) | CAR-T | Neoplasms | CD19 inhibitors CD3ζ inhibitors | Nanjing Legend Biotech Co., Ltd. | Nanjing Legend Biotech Co., Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | CD19/CD247 CAR-T (Nanjing Legend Biotech ) | - | - | detail > | |
| RG-1970 | RG-1970 | CAR-NK | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD19 inhibitors CD70 inhibitors | Hangzhou RonGu Biotechnology Co., Ltd. | Hangzhou RonGu Biotechnology Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | RG-1970 | - | - | detail > | |
| CD3/CD19 XFab (Immunoah) | CD3/CD19 XFab (Immunoah) | Bispecific T-cell Engager (BiTE) | Other Diseases | CD19 inhibitors CD3 stimulants | Beijng Immunoah Pharma Tech Co., Ltd | Beijng Immunoah Pharma Tech Co., Ltd | Preclinical | - | - | - | - | - | - | - | - | - | CD3/CD19 XFab (Immunoah) | - | - | detail > | |
| In vivo CD3-targeted lentivecto delivery of CD19 CAR (EXUMA Biotech Corp.) | In vivo CD3-targeted lentivecto delivery of CD19 CAR (EXUMA Biotech Corp.) | in vivo CAR-T therapy | Neoplasms Hemic and Lymphatic Diseases | CD19 modulators CD3 stimulants | EXUMA Biotech Corp. | EXUMA Biotech Corp. | Preclinical | - | - | - | - | - | - | - | - | - | In vivo CD3-targeted lentivecto delivery of CD19 CAR (EXUMA Biotech Corp.) | - | - | detail > | |
| ADAM17 KO CD19 CAR-NK (Nkarta) | ADAM17 KO CD19 CAR-NK (Nkarta) | CAR-NK | Neoplasms Hemic and Lymphatic Diseases | CD19 inhibitors ADCC | Nkarta, Inc. | Calico LLCNkarta, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | ADAM17 KO CD19 CAR-NK (Nkarta) | - | - | detail > |
Total 934 data
1
2
3
4
5
6
...
93
94
